Maldives vs Syria: Access to anti-retroviral drugs, male (%)
Maldives
60.0%
in 2024
Syria
59.0%
in 2024
Maldives rank
102nd
Syria rank
105th
Access to anti-retroviral drugs, male (%) over time
- Maldives
- Syria
How they compare
Maldives currently reports 60.0% against 59.0% in Syria, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Syria ahead.
Maldives ranks 102nd and Syria ranks 105th of 141 countries.
Maldives has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Maldives | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 29.4% | 2.5% | 26.9% | Maldives |
| 2010s | 34.2% | 21.2% | 13.0% | Maldives |
| 2020s | 54.2% | 51.6% | 2.6% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Maldives or Syria?
- Maldives, at 60.0% against 59.0% in Syria as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Maldives and Syria?
- 1.0%, with Maldives ahead.
- How many years of comparable data are there for Maldives and Syria?
- 25 years are reported by both, from 2000 to 2024.
- How do Maldives and Syria rank globally for access to anti-retroviral drugs, male?
- Maldives ranks 102nd and Syria ranks 105th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.